Andrew Booth has bought ABCL on 4 days since Nov 2021

Andrew Booth is the Chief Financial Officer (CFO) of AbCellera Biologics Inc. (ABCL), a biotechnology company focused on discovering and developing antibody medicines. He joined as CFO in August 2019 after serving nearly four years on the company's Board of Directors since 2016, playing a key role in AbCellera's initial public offering on Nasdaq in 2020.(

Booth brings extensive experience in scaling life sciences companies. Prior to AbCellera, he spent 10 years at STEMCELL Technologies in roles including CFO, Chief Commercial Officer, and VP of Instrumentation, helping grow the company from $40 million in revenue and 250 employees to $250 million and over 1,300 employees.( Earlier, he spent seven years at General Electric, leading M&A and business development for GE Healthcare’s Europe, Middle East, and Africa business and its global Life Sciences division.( He holds an MBA from INSEAD and a BASc in Engineering Physics from the University of British Columbia, and serves as an advisor to Aspect Biosystems and others, including a recent board appointment at Aspect in May 2025.(

Written by Perplexity from public sources.